Everest Medicines’ NEFECON® Gains Full Approval in China for IgAN Treatment

Everest Medicines Ltd. ( (HK:1952) ) has shared an announcement.

Everest Medicines Ltd. announced that its drug NEFECON® has received full approval from China’s National Medical Products Administration for treating primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. This approval marks NEFECON® as the first etiological treatment for IgAN to receive such approval in China, and it is already approved in the U.S. and Europe. The approval is based on successful results from the global Phase 3 NefIgArd clinical trial, which demonstrated significant benefits in kidney function and disease progression delay. NEFECON® is now commercially available in several regions, with further launches anticipated, potentially enhancing Everest Medicines’ market position and offering substantial benefits to IgAN patients.

More about Everest Medicines Ltd.

Everest Medicines Ltd. is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products in the fields of oncology, autoimmune disorders, and infectious diseases. The company operates primarily in mainland China, Hong Kong, Macau, Taiwan, Singapore, and South Korea.

Average Trading Volume: 5,750,100

Technical Sentiment Signal: Buy

Current Market Cap: HK$16.59B

For an in-depth examination of 1952 stock, go to TipRanks’ Stock Analysis page.